Arcus Biosciences, Inc. (RCUS) Dividend History

Company News

• Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

  The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent progress and upcoming studies from several companies in the oncology space.

  Benzinga

  Featured Companies: AKYA BCTX CKPT ONCY
• Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033

  The global retinoblastoma treatment market is projected to grow from $1.93 billion in 2023 to $2.03 billion in 2024, driven by factors like increased funding, cancer research, and technological advancements. The market is expected to reach $2.56 billion by 2028, growing at a CAGR of 5.9%.

  GlobeNewswire Inc.

  Featured Companies: BAX BMY JNJ LLY MRK PFE PHIO REGN
• Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences - Arcus Biosciences (NYSE:RCUS) - Benzinga

  Arcus Biosciences (RCUS) underwent analysis by 4 analysts in the last quarter, with a downward trend in their 12-month price targets. The article provides a detailed breakdown of the analysts' recent evaluations, ratings, and price targets for the company.

  Benzinga
• Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?

  Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

  Zacks Investment Research
• Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study

  Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.

  Zacks Investment Research

  Featured Companies: ALXO GILD KRYS